Almirall, S.A., a pharmaceutical company, researches, develops, manufactures, and markets proprietary and licensed medicines worldwide. The company offers its products for dermatological diseases comprising actinic keratosis, psoriasis, eczema, and skin infections; and gastrointestinal diseases, such as irritable bowel syndrome, as well as for pain. Its products include LAS100977, a potent bronchodilator, which is in phase IIa clinical trial for the treatment of asthma and chronic obstructive pulmonary disease (COPD); LAS190792, a dual long-acting muscarinic antagonist ß2 agonist that is in Phase I clinical for treating COPD; and LAS40464, an aclidinium bromide and formoterol for the treatment of COPD. The company also develops LAS41004, a compound that is in Phase II clinical trials for the treatment of psoriasis and/or atopic dermatitis; LAS41008, which is in Phase III clinical trial for treating psoriasis; and Sativex, an oromucosal spray is in Phase III clinical trial for the treatment of spasticity in patients with multiple sclerosis. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.
almirall sa (ALM:Continuous)
General Mitre, 151
Phone: 34 93 291 30 00
|H Lundbeck A/S||kr132.80 DKK||-0.70|
|Ironwood Pharmaceuticals Inc||$13.64 USD||0.00|
|Nektar Therapeutics||$11.48 USD||0.00|
|Santen Pharmaceutical Co Ltd||¥1,804 JPY||+8.00|
|Synergy Health PLC||1,801 GBp||-12.00|
|View Industry Companies|
Sponsored Financial Commentaries
To contact ALMIRALL SA, please visit www.almirall.com. Company data is provided by Capital IQ. Please use this form to report any data issues.